Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy
- Diabetic nephropathy is one of the most frequent, devastating and costly complications of diabetes. The available therapeutic approaches are limited. Dipeptidyl peptidase type 4 (DPP-4) inhibitors represent a new class of glucose-lowering drugs that might also have reno-protective properties. DPP-4 exists in two forms: a plasma membranebound form and a soluble form, and can exert many biological actions mainly through its peptidase activity and interaction with extracellular matrix components. The kidneys have the highest DPP-4 expression level in mammalians. DPP-4 expression and urinary activity are up-regulated in diabetic nephropathy, highlighting its role as a potential target to manage diabetic nephropathy. Preclinical animal studies and some clinical data suggest that DPP-4 inhibitors decrease the progression of diabetic nephropathy in a blood pressure-and glucose-independent manner. Many studies reported that these reno-protective effects could be due to increased half-life of DPP-4 substrates such as glucagon-like peptide-1Diabetic nephropathy is one of the most frequent, devastating and costly complications of diabetes. The available therapeutic approaches are limited. Dipeptidyl peptidase type 4 (DPP-4) inhibitors represent a new class of glucose-lowering drugs that might also have reno-protective properties. DPP-4 exists in two forms: a plasma membranebound form and a soluble form, and can exert many biological actions mainly through its peptidase activity and interaction with extracellular matrix components. The kidneys have the highest DPP-4 expression level in mammalians. DPP-4 expression and urinary activity are up-regulated in diabetic nephropathy, highlighting its role as a potential target to manage diabetic nephropathy. Preclinical animal studies and some clinical data suggest that DPP-4 inhibitors decrease the progression of diabetic nephropathy in a blood pressure-and glucose-independent manner. Many studies reported that these reno-protective effects could be due to increased half-life of DPP-4 substrates such as glucagon-like peptide-1 (GLP-1) and stromal derived factor-1 alpha (SDF-1a). However, the underlying mechanisms are far from being completely understood and clearly need further investigations.…
Verfasserangaben: | Ahmed Abdallah Abdalrahman Mohamed HasanORCiDGND, Berthold HocherORCiDGND |
---|---|
DOI: | https://doi.org/10.1530/JME-17-0005 |
ISSN: | 0952-5041 |
ISSN: | 1479-6813 |
Pubmed ID: | https://pubmed.ncbi.nlm.nih.gov/28420715 |
Titel des übergeordneten Werks (Englisch): | Journal of Molecular Endocrinology |
Verlag: | Bioscientifica LTD |
Verlagsort: | Bristol |
Publikationstyp: | Rezension |
Sprache: | Englisch |
Datum der Erstveröffentlichung: | 18.04.2017 |
Erscheinungsjahr: | 2017 |
Datum der Freischaltung: | 14.04.2022 |
Freies Schlagwort / Tag: | DPP-4; DPP-4 inhibitors; GLP-1 and SDF-1a; diabetic nephropathy |
Band: | 59 |
Seitenanzahl: | 10 |
Erste Seite: | R1 |
Letzte Seite: | R10 |
Fördernde Institution: | Boehringer Ingelheim; manufacturer of linagliptin |
Organisationseinheiten: | Mathematisch-Naturwissenschaftliche Fakultät / Institut für Biochemie und Biologie |
DDC-Klassifikation: | 5 Naturwissenschaften und Mathematik / 57 Biowissenschaften; Biologie / 570 Biowissenschaften; Biologie |
Peer Review: | Referiert |
Publikationsweg: | Open Access / Bronze Open-Access |